The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
ConclusionsChanges in pricing policy and the public reimbursement scheme related to the market entry of biosimilars were the main reasons for the decrease in the prices of reference products. Therefore, biosimilars did not generate genuine price competition between biological products. In many of the drug groups examined, the market shares of biosimilars have growth potential in the future.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Enbrel | Filgrastim | Finland Health | Forteo | Health Insurance | Humalog | Humira | Insulin | Insurance | Lantus | Lovenox | Neulasta | Neupogen | Nutropin AQ | Study